Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.53 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32691552 | 0.98 | SLC6A2 (0.67) | SLC6A2C5AR1OPRD1OPRM1F2 | |
| SCHEMBL32691571 | 0.97 | SLC6A2 (0.64) | SLC6A2C5AR1OPRD1OPRM1REN | |
| SCHEMBL32691265 | 0.95 | SLC6A2 (0.62) | SLC6A2C5AR1OPRD1OPRM1REN | |
| SCHEMBL32691458 | 0.94 | SLC6A2 (0.61) | SLC6A2C5AR1OPRD1OPRM1F2 | |
| SCHEMBL32691451 | 0.92 | SLC6A2 (0.59) | SLC6A2C5AR1OPRD1OPRM1F2 | |
| SCHEMBL31127566 | 0.91 | OPRM1 (0.60) | SLC6A2C5AR1OPRD1OPRM1F2 | |
| SCHEMBL29461549 | 0.90 | F2 (0.60) | SLC6A2OPRD1OPRM1F2REN | |
| SCHEMBL29402848 | 0.89 | SLC6A2 (0.77) | SLC6A2OPRD1OPRM1F2NTSR2 | |
| SCHEMBL29353395 | 0.89 | SLC6A2 (0.77) | SLC6A2OPRD1OPRM1F2NTSR2 | |
| SCHEMBL31276072 | 0.89 | SLC6A2 (0.69) | SLC6A2F2REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | CHENGDU AODA BIOTECHNOLOGY CO LTD (CN) | 2026-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085103-A1 | LONG-ACTING INSULIN COMPOUND | IAPP, INSR, IDE | SLC6A2 2535/4885C5AR1 1779/4885OPRD1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.